KURA ONCOLOGY, INC. Deferred Tax Assets, Operating Loss Carryforwards
KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, Operating Loss Carryforwards of $111.46 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $111.46M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $97.61M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $144.45M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $125.99M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $111.46M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $97.61M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $144.45M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $125.99M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $111.24M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $79.23M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $53.59M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $37.33M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $22.05M 10-K · filed 2019-03-05 | |
| 2016-12-31 | $18.32M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $7.97M 10-K · filed 2017-03-14 | |
| 2014-12-31 | $442.00K 10-K · filed 2016-03-17 | $8.20K 10-K · filed 2015-02-27 |
| 2013-12-31 | $5.80K 10-K · filed 2015-02-27 | |
| 2012-12-31 | $3.80K 10-K · filed 2014-03-31 | |
| 2011-12-31 | $2.20K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |